Zoetis Inc. $ZTS Stock Holdings Lifted by Entropy Technologies LP

Key Points

• Entropy Technologies LP boosted its Zoetis stake by 67% in the fourth quarter, ending with 53,175 shares worth about $6.69 million. Other institutional investors also added modestly, and hedge funds and institutions now own 92.8% of the stock.
• Wall Street sentiment remains mixed: analysts currently have a Hold consensus on Zoetis, with a consensus price target of $133.92. Recent reports included both hold and buy calls, while some firms trimmed targets or downgraded the stock.
• Zoetis is facing a legal overhang from multiple securities-fraud class-action notices tied to alleged misrepresentations about veterinarian adoption and prescription trends. The company also recently missed Q1 earnings and revenue estimates, adding to investor caution despite its dividend and solid profitability metrics.

Entropy Technologies LP lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 67.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 53,175 shares of the company's stock after acquiring an additional 21,330 shares during the period. Entropy Technologies LP's holdings in Zoetis were worth $6,690,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. RFG Advisory LLC increased its position in shares of Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock worth $215,000 after acquiring an additional 80 shares in the last quarter. YANKCOM Partnership boosted its holdings in shares of Zoetis by 3.5% during the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company's stock worth $302,000 after purchasing an additional 81 shares during the period. Beese Fulmer Investment Management Inc. boosted its holdings in shares of Zoetis by 2.4% during the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company's stock worth $537,000 after purchasing an additional 85 shares during the period. Quest 10 Wealth Builders Inc. boosted its holdings in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company's stock worth $240,000 after purchasing an additional 86 shares during the period. Finally, Financial Engines Advisors L.L.C. boosted its holdings in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after purchasing an additional 87 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Argus restated a "hold" rating on shares of Zoetis in a report on Wednesday, May 27th. Stifel Nicolaus decreased their price target on shares of Zoetis from $105.00 to $95.00 and set a "hold" rating for the company in a report on Friday, May 22nd. Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. BTIG Research restated a "buy" rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Finally, Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. NYSE: ZTS until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

Zoetis Price Performance

Shares of ZTS opened at $79.51 on Friday. The firm has a market cap of $33.33 billion, a PE ratio of 13.19, a PEG ratio of 1.24 and a beta of 0.75. The firm's 50 day moving average price is $96.94 and its 200 day moving average price is $114.22. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $167.38.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis's revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis's dividend payout ratio (DPR) is presently 35.16%.

Insider Activity at Zoetis

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the business's stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director owned 27,862 shares of the company's stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.